title: Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
abstract: The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.
authors.affiliation: Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
authors.forename: Chadwan
authors.initials: C
authors.lastname: Al Yaghchi
authors.affiliation: National Centre for International Research in Cell & Gene Therapy, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, China.
authors.forename: Zhongxian
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
authors.forename: Ghassan
authors.initials: G
authors.lastname: Alusi
authors.affiliation: Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.|National Centre for International Research in Cell & Gene Therapy, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, China.
authors.forename: Nicholas R
authors.initials: NR
authors.lastname: Lemoine
authors.affiliation: Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, UK.|National Centre for International Research in Cell & Gene Therapy, Sino-British Research Centre for Molecular Oncology, Zhengzhou University, China.
authors.forename: Yaohe
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005822:Genetic Vectors; D006801:Humans; D016233:Immunotherapy, Active / Q000639:trends; D008562:Membrane Glycoproteins / Q000627:therapeutic use; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000628:therapy*; D014616:Vaccinia virus / Q000276:immunology*; D014779:Virus Replication; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; C518274:Panvac-VF; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: immunotherapy; oncolytic virus; pancreatic cancer; vaccinia virus